XML 72 R73.htm IDEA: XBRL DOCUMENT v3.19.3
Note 14 - License, Collaboration and Distribution Agreements (Details Textual) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 01, 2013
Feb. 07, 2012
Apr. 30, 2013
Jan. 31, 2013
Oct. 31, 2012
Sep. 30, 2012
Jan. 31, 2012
Oct. 31, 2012
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2014
Dec. 31, 2018
Contract with Customer, Liability, Total                 $ 0   $ 0     $ 41,000
Partner Pharmacies [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                            
Concentration Risk, Percentage                 20.00% 9.00% 23.00% 9.00%    
Avenova Direct [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                            
Concentration Risk, Percentage                 21.00%   8.00%      
Reallocated from Deferred Revenue [Member]                            
Stockholders' Equity, Period Increase (Decrease), Total               $ 600,000            
China Pioneer [Member]                            
Proceeds from Issuance or Sale of Equity, Total           $ 2,500,000                
Unit Purchase Agreement Shares Per Unit           1                
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right           1                
Excess Fair Value Over Proceeds Received From Purchase               $ 1,000,000            
China Pioneer [Member] | Tranche One [Member]                            
Purchase Agreement Units           800,000                
China Pioneer [Member] | Tranche Two [Member]                            
Purchase Agreement Units         1,200,000                  
Purchase Agreement Unit Price Per Share         $ 1.25                  
Purchase Unit Agreement Total Units Fair Value         $ 3,500,000                  
China Pioneer [Member] | Neutrophase [Member]                            
Proceeds from Collaborators       $ 312,500     $ 312,500           $ 625,000  
Maximum Possible Sales Discounts           $ 500,000                
Integrated Healing Technologies, LLC [Member] | Neutrophase [Member]                            
Proceeds from Collaborators   $ 750,000                        
Virbac [Member] | Auriclosene (NVC-422) [Member]                            
Proceeds from Collaborators     $ 250,000                      
Principal Business Enterprise, Inc. [Member] | Neutrophase [Member]                            
Proceeds from Collaborators $ 200,000                          
China Pioneer and Principal Business Enterprise Inc. [Member] | Samples and Future Products [Member]                            
Contract with Customer, Liability, Revenue Recognized                 $ 0 $ 0 $ 41,000 $ 13,000    
McKesson Corporation [Member] | Avenova Product [Member]                            
Contract with Customer, Liability, Revenue Recognized                 1,100,000 $ 2,500,000 3,600,000 $ 6,900,000    
McKesson Corporation [Member] | Avenova Product [Member] | Accounts Payable and Accrued Liabilities [Member]                            
Contract with Customer, Liability, Total                 500,000   500,000     1,400,000
McKesson Corporation [Member] | Avenova Product [Member] | Prepaid Expenses and Other Current Assets [Member]                            
Contract with Customer, Rebate Liability, Current                 $ 600,000   $ 600,000     $ 900,000